Literature DB >> 15507291

Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies.

Angela Tincani1, Flavio Allegri, Genesio Balestrieri, Guido Reber, Marielle Sanmarco, Pierluigi Meroni, Marie-Claire Boffa.   

Abstract

Antiphospholipid ELISAs are part of the Antiphospholipid Antibodies Syndrome classification criteria, having the same diagnostic value as lupus anticoagulant. However, sometimes their results appear scarcely meaningful especially when wide metanalyses studies are performed, probably because of their well-known inter-laboratory variability. The application of a common protocol was shown to improve the test reproducibility, but this observation did not have any influence on the routine performances. After discussion among experts at the European level, we identified four conditions named "minimal requirements" considered useful to decrease the inter-laboratory variability: (1) to run the samples in duplicate; (2) to determine the cut off level in each laboratory analysing at least 50 samples from normal subjects, possibly age- and sex-matched with the patient population usually attending the Centre; (3) to calculate the cut-off level in percentiles; (4) to use stable external control in the tests. A collaborative study involving 36 European centres proved that the use of monoclonal anti-beta2 glycoprotein I antibodies, HCAL (IgG) and EY2C9 (IgM) as standards, can help to reduce the inter-laboratory coefficient of variation both in anticardiolipin (aCL) and anti-beta2GPI (anti-beta2 glycoprotein I) ELISA. Therefore, we propose HCAL and EY2C9 as external controls, but other monoclonal or polyclonal preparations may be considered. During an interactive workshop held last May in Italy, 16 companies producing these tests agreed to consider the introduction of the "requirements" in their products. We suggest to adopt these "requirements" particularly in clinical studies, in order to compare more easily the literature data.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507291     DOI: 10.1016/j.thromres.2004.06.035

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Detection of anticardiolipin antibody IgG by time-resolved fluoroimmunoassay.

Authors:  Yan Ye; Zhigang Hu; Jie Liu; Guoqian Chen; Yaohong Zhou; Lei Yu
Journal:  Clin Rheumatol       Date:  2012-06-10       Impact factor: 2.980

2.  A new Eu(3+)-labeled method for anticardiolipin antibody IgM.

Authors:  Yan Ye; Zhigang Hu; Jie Liu; Guoqian Chen; Yaohong Zhou
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

3.  Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome.

Authors:  Panagiotis Grypiotis; Amelia Ruffatti; Vittorio Pengo; Marta Tonello; Alessandra Biasiolo; Daniela Zamboni; Anna Cavazzana; Silvano Todesco
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

4.  Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome.

Authors:  Entela Nuri; Mara Taraborelli; Laura Andreoli; Marta Tonello; Maria Gerosa; Antonia Calligaro; Lorenza Maria Argolini; Rajesh Kumar; Vittorio Pengo; Pier Luigi Meroni; Amelia Ruffatti; Angela Tincani
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 5.  Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases.

Authors:  Pier Luigi Meroni; Martina Biggioggero; Silvia S Pierangeli; Joanna Sheldon; Ingrid Zegers; Maria Orietta Borghi
Journal:  Nat Rev Rheumatol       Date:  2013-11-26       Impact factor: 20.543

6.  Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.

Authors:  Tomasz Hawro; Andrzej Bogucki; Maria Krupińska-Kun; Marcus Maurer; Anna Woźniacka
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

7.  Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies.

Authors:  Maria-Grazia Lazzaroni; Micaela Fredi; Laura Andreoli; Cecilia Beatrice Chighizola; Teresa Del Ross; Maria Gerosa; Anna Kuzenko; Maria-Gabriella Raimondo; Andrea Lojacono; Francesca Ramazzotto; Sonia Zatti; Laura Trespidi; Pier-Luigi Meroni; Vittorio Pengo; Amelia Ruffatti; Angela Tincani
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

8.  Multiple presence of prothrombotic risk factors in Croatian children with arterial ischemic stroke and transient ischemic attack.

Authors:  Jasna Leniček Krleža; Vlasta Ðuranović; Ana Bronić; Desiree Coen Herak; Vlatka Mejaški-Bošnjak; Renata Zadro
Journal:  Croat Med J       Date:  2013-08       Impact factor: 1.351

9.  The Clinical Performance of a New Chemiluminescent Immunoassay in Measuring Anti-β2 Glycoprotein 1 and Anti-Cardiolipin Antibodies.

Authors:  Jiansuo Zhou; Xiuzhu Hou; Hua Zhang; Tiancheng Wang; Liyan Cui
Journal:  Med Sci Monit       Date:  2018-09-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.